Results from Mendelian randomization analyses revealed PsO and PsA did not increase the risk of basal cell carcinoma, cutaneous squamous cell carcinoma, or cutaneous melanoma.
Perioperative treatment with cemiplimab continued to produce signs of efficacy in patients with resectable stage II to IV cutaneous squamous cell carcinoma.
10.08.2023 - • Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor INF904 progressing in single ascending dose (SAD) and multiple ascending .
1. In this Norwegian study, patients receiving organ transplants with cutaneous squamous cell carcinoma (cSCC) had higher rates of developing a second cSCC, metastasis, and death from cSCC when compared to patients with cSCC not receiving organ transplants. 2. In order to ensure proper follow-up and skin cancer care policies, clinicians should be aware of
Sunandana Chandra, MD, MS, Anna C. Pavlick, DO, MSc, MBA, BSN, and Nikhil Khushalani, MD, discuss the importance of multidisciplinary care in CSCC and patient counseling regarding available therapies.